TOKYO--(BUSINESS WIRE)--Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter �Solasia�) officially announced today that an organoarsenic drug �DARVIAS� Injection 135mg� (SP-02, hereinafter DARVIAS�) has been launched today in Japan for use in relapsed or refractory Peripheral T-Cell Lymphoma. DARVIAS� will be commercialized by Nippon Kayaku Co., Ltd. (TOKYO:4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto).

Contacts

Solasia Pharma K.K.
Toyokazu Ohata, Public Relations and Investor Relations

Tel: +81 3 5843 8046 (TOKYO)

[email protected]